Gap finder
Search review questions
Each row is one question a systematic review asked: who, what, compared with what, and which outcome, with the effect it found and how certain that is. Words match anywhere in the field.
420 questions in 57 reviews · Gut
current versionsNo studies 420 · 100%Ungraded 0 · 0%Very low 0 · 0%Low 0 · 0%Moderate 0 · 0%High 0 · 0%
Ungraded means an effect was reported without a GRADE rating; it is not a gap. No studies means the review found nothing to answer the question. The six categories are a display order, not a score.
| Question | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Yoga intervention vs no treatment (both groups received standard medical therapy) Abdominal pain frequency or change in frequency · people with inflammatory bowel disease Interventions for the management of abdominal pain in Crohn's disease and inflammatory bowel disease (2021) · Cochrane | no estimate extracted | NR | No studies |
Yoga intervention vs no treatment (both groups received standard medical therapy) Abdominal pain intensity or change in intensity · people with inflammatory bowel disease Interventions for the management of abdominal pain in Crohn's disease and inflammatory bowel disease (2021) · Cochrane | no estimate extracted | NR | No studies |
Transcranial direct current stimulation vs sham stimulation Treatment success as defined by the authors · people with inflammatory bowel disease Interventions for the management of abdominal pain in Crohn's disease and inflammatory bowel disease (2021) · Cochrane | no estimate extracted | NR | No studies |
Transcranial direct current stimulation vs sham stimulation Abdominal pain frequency or change in frequency · people with inflammatory bowel disease Interventions for the management of abdominal pain in Crohn's disease and inflammatory bowel disease (2021) · Cochrane | no estimate extracted | NR | No studies |
Kefir ( Lactobacillus bacteria) vs no intervention Treatment success as defined by the authors · people with inflammatory bowel disease Interventions for the management of abdominal pain in Crohn's disease and inflammatory bowel disease (2021) · Cochrane | no estimate extracted | NR | No studies |
Kefir ( Lactobacillus bacteria) vs no intervention Abdominal pain frequency or change in frequency · people with inflammatory bowel disease Interventions for the management of abdominal pain in Crohn's disease and inflammatory bowel disease (2021) · Cochrane | no estimate extracted | NR | No studies |
Medicine‐separated moxibustion combined with acupuncture vs wheat bran‐separated moxibustion combined with shallow acupuncture Treatment success as defined by the authors · people with Crohn's disease Interventions for the management of abdominal pain in Crohn's disease and inflammatory bowel disease (2021) · Cochrane | no estimate extracted | NR | No studies |
Low FODMAPs diet vs sham diet Treatment success as defined by the authors · UC patients Interventions for the management of abdominal pain in ulcerative colitis (2021) · Cochrane | no estimate extracted | NR | No studies |
Relaxation training vs wait‐list Withdrawals due to adverse events · UC patients Interventions for the management of abdominal pain in ulcerative colitis (2021) · Cochrane | no estimate extracted | NR | No studies |
Yoga intervention vs no intervention Treatment success as defined by the authors · UC patients Interventions for the management of abdominal pain in ulcerative colitis (2021) · Cochrane | no estimate extracted | NR | No studies |
Yoga intervention vs no intervention Pain frequency · UC patients Interventions for the management of abdominal pain in ulcerative colitis (2021) · Cochrane | no estimate extracted | NR | No studies |
Yoga intervention vs no intervention Pain intensity · UC patients Interventions for the management of abdominal pain in ulcerative colitis (2021) · Cochrane | no estimate extracted | NR | No studies |
Kefir vs no intervention Treatment success as defined by the authors · UC patients Interventions for the management of abdominal pain in ulcerative colitis (2021) · Cochrane | no estimate extracted | NR | No studies |
Kefir vs no intervention Pain frequency · UC patients Interventions for the management of abdominal pain in ulcerative colitis (2021) · Cochrane | no estimate extracted | NR | No studies |
Stellate ganglion block vs sulphasalazine Treatment success as defined by the authors · UC patients Interventions for the management of abdominal pain in ulcerative colitis (2021) · Cochrane | no estimate extracted | NR | No studies |
Stellate ganglion block vs sulphasalazine Pain frequency · UC patients Interventions for the management of abdominal pain in ulcerative colitis (2021) · Cochrane | no estimate extracted | NR | No studies |
Stellate ganglion block vs sulphasalazine Pain intensity (measure on a 0‐3 four‐point scale) · UC patients Interventions for the management of abdominal pain in ulcerative colitis (2021) · Cochrane | no estimate extracted | NR | No studies |
Stellate ganglion block vs sulphasalazine Withdrawals due to adverse events · UC patients Interventions for the management of abdominal pain in ulcerative colitis (2021) · Cochrane | no estimate extracted | NR | No studies |
Relaxation training vs wait‐list Treatment success as defined by the authors · UC patients Interventions for the management of abdominal pain in ulcerative colitis (2021) · Cochrane | no estimate extracted | NR | No studies |
Oral 5‐ASA vs SASP Failure to induce endoscopic remission · People with active mild‐to‐moderate ulcerative colitis Oral 5‐aminosalicylic acid for induction of remission in ulcerative colitis (2020) · Cochrane | no estimate extracted | NR | No studies |
Oral 5‐ASA vs SASP Failure to adhere to medication regimen · People with active mild‐to‐moderate ulcerative colitis Oral 5‐aminosalicylic acid for induction of remission in ulcerative colitis (2020) · Cochrane | no estimate extracted | NR | No studies |
Oral 5‐ASA vs comparator 5‐ASA Failure to induce endoscopic remission · People with active mild‐to‐moderate ulcerative colitis Oral 5‐aminosalicylic acid for induction of remission in ulcerative colitis (2020) · Cochrane | no estimate extracted | NR | No studies |
Oral 5‐ASA vs comparator 5‐ASA Failure to adhere to medication regimen · People with active mild‐to‐moderate ulcerative colitis Oral 5‐aminosalicylic acid for induction of remission in ulcerative colitis (2020) · Cochrane | no estimate extracted | NR | No studies |
Oral 5‐ASA vs placebo Failure to adhere to medication regimen · People with active mild‐to‐moderate ulcerative colitis Oral 5‐aminosalicylic acid for induction of remission in ulcerative colitis (2020) · Cochrane | no estimate extracted | NR | No studies |
Oral 5‐aminosalicylic acid vs sulfasalazine Serious adverse events · people with quiescent ulcerative colitis Oral 5‐aminosalicylic acid for maintenance of remission in ulcerative colitis (2020) · Cochrane | no estimate extracted | NR | No studies |
Oral 5‐aminosalicylic acid vs placebo Failure to adhere to study medication · people with quiescent UC Oral 5‐aminosalicylic acid for maintenance of remission in ulcerative colitis (2020) · Cochrane | no estimate extracted | NR | No studies |
Oral 5‐aminosalicylic acid vs comparator 5‐aminosalicylic acid formulation Failure to adhere to study medication regimen · people with quiescent UC Oral 5‐aminosalicylic acid for maintenance of remission in ulcerative colitis (2020) · Cochrane | no estimate extracted | NR | No studies |
Oral 5‐aminosalicylic acid vs sulfasalazine Failure to adhere to study medication · people with quiescent ulcerative colitis Oral 5‐aminosalicylic acid for maintenance of remission in ulcerative colitis (2020) · Cochrane | no estimate extracted | NR | No studies |
Probiotics vs 5‐aminosalicylic acid (5‐ASA) (mesalazine) Disease improvement · people with active ulcerative colitis Probiotics for induction of remission in ulcerative colitis (2020) · Cochrane | no estimate extracted | NR | No studies |
Probiotics plus 5‐aminosalicylic acid (5‐ASA) (mesalazine) vs 5‐aminosalicylic acid (5‐ASA) (mesalazine) Disease improvement · people with active ulcerative colitis Probiotics for induction of remission in ulcerative colitis (2020) · Cochrane | no estimate extracted | NR | No studies |
Probiotics plus 5‐aminosalicylic acid (5‐ASA) (mesalazine) vs 5‐aminosalicylic acid (5‐ASA) (mesalazine) Minor adverse events · people with active ulcerative colitis Probiotics for induction of remission in ulcerative colitis (2020) · Cochrane | no estimate extracted | NR | No studies |
Probiotics plus 5‐aminosalicylic acid (5‐ASA) (mesalazine) vs 5‐aminosalicylic acid (5‐ASA) (mesalazine) Serious adverse events · people with active ulcerative colitis Probiotics for induction of remission in ulcerative colitis (2020) · Cochrane | no estimate extracted | NR | No studies |
Probiotics plus 5‐aminosalicylic acid (5‐ASA) (mesalazine) vs 5‐aminosalicylic acid (5‐ASA) (mesalazine) Withdrawal due to adverse events · people with active ulcerative colitis Probiotics for induction of remission in ulcerative colitis (2020) · Cochrane | no estimate extracted | NR | No studies |
Probiotics vs 5‐aminosalicylic acid (5‐ASA) (mesalazine) Need for additional therapy · people with ulcerative colitis in remission Probiotics for maintenance of remission in ulcerative colitis (2020) · Cochrane | no estimate extracted | NR | No studies |
Probiotic + 5‐aminosalicylic acid (5‐ASA) (mesalazine) vs 5‐ASA (mesalazine) Serious adverse events · people with ulcerative colitis in remission Probiotics for maintenance of remission in ulcerative colitis (2020) · Cochrane | no estimate extracted | NR | No studies |
Probiotic + 5‐aminosalicylic acid (5‐ASA) (mesalazine) vs 5‐ASA (mesalazine) Need for additional therapy · people with ulcerative colitis in remission Probiotics for maintenance of remission in ulcerative colitis (2020) · Cochrane | no estimate extracted | NR | No studies |
Probiotic + 5‐aminosalicylic acid (5‐ASA) (mesalazine) vs 5‐ASA (mesalazine) Health‐related quality of life · people with ulcerative colitis in remission Probiotics for maintenance of remission in ulcerative colitis (2020) · Cochrane | no estimate extracted | NR | No studies |
Probiotics vs placebo Need for additional therapy · people with ulcerative colitis in remission Probiotics for maintenance of remission in ulcerative colitis (2020) · Cochrane | no estimate extracted | NR | No studies |
CBT with therapist support vs fatigue information leaflet only Adverse events · participants with IBD Interventions for fatigue in inflammatory bowel disease (2020) · Cochrane | no estimate extracted | NR | No studies |
CBT with therapist support vs fatigue information leaflet only Serious adverse events · participants with IBD Interventions for fatigue in inflammatory bowel disease (2020) · Cochrane | no estimate extracted | NR | No studies |
CBT with therapist support vs fatigue information leaflet only Withdrawal due to adverse events · participants with IBD Interventions for fatigue in inflammatory bowel disease (2020) · Cochrane | no estimate extracted | NR | No studies |
Physical activity advice plus omega 3 vs no physical activity advice plus omega 3 Serious adverse events · participants with quiescent IBD Interventions for fatigue in inflammatory bowel disease (2020) · Cochrane | no estimate extracted | NR | No studies |
Physical activity advice plus omega 3 vs no physical activity advice plus omega 3 Withdrawal due to adverse events · participants with quiescent IBD Interventions for fatigue in inflammatory bowel disease (2020) · Cochrane | no estimate extracted | NR | No studies |
Physical activity advice plus placebo vs no physical activity advice plus placebo Serious adverse events ‐ not reported · participants with quiescent IBD Interventions for fatigue in inflammatory bowel disease (2020) · Cochrane | no estimate extracted | NR | No studies |
Physical activity advice plus placebo vs no physical activity advice plus placebo Withdrawal due to adverse events ‐ not reported · participants with quiescent IBD Interventions for fatigue in inflammatory bowel disease (2020) · Cochrane | no estimate extracted | NR | No studies |
Physical activity advice plus placebo vs no physical activity advice plus omega 3 Serious adverse events ‐ not reported · participants with quiescent IBD Interventions for fatigue in inflammatory bowel disease (2020) · Cochrane | no estimate extracted | NR | No studies |
Physical activity advice plus placebo vs no physical activity advice plus omega 3 Withdrawal due to adverse events ‐ not reported · participants with quiescent IBD Interventions for fatigue in inflammatory bowel disease (2020) · Cochrane | no estimate extracted | NR | No studies |
Initiation of prophylactic therapy guided by colonoscopy vs initiation of prophylactic therapy immediately after surgery Quality of life · Adult participants (> 16 years of age) undergoing intestinal resection due to Crohn's disease. Colonoscopy‐guided therapy for the prevention of post‐operative recurrence of Crohn’s disease (2020) · Cochrane | no estimate extracted | NR | No studies |
Intensification of prophylactic therapy guided by colonoscopy vs intensification guided by clinical recurrence Quality of life · adult participants (> 16 years of age) undergoing intestinal resection due to Crohn's disease Colonoscopy‐guided therapy for the prevention of post‐operative recurrence of Crohn’s disease (2020) · Cochrane | no estimate extracted | NR | No studies |
Adalimumab vs active comparator Adverse events · People with quiescent Crohn's disease (ileocolic resection) Adalimumab for maintenance of remission in Crohn's disease (2020) · Cochrane | no estimate extracted | NR | No studies |